Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 6, 2004, Pages 928-

  Francis, D L ^a,b   Visvikis, D ^a   Costa, D C ^a   Croasdale, I ^a   Arulampalam, T H ^b   Luthra, S K ^c   Taylor, I ^b   Ell, P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CARCINOMA; DIAGNOSTIC VALUE; HUMAN; POSITRON EMISSION TOMOGRAPHY; RELIABILITY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 2942560331     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1438-0     Document Type: Article

References (2)

1. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A:1924-1927.
2. 18F]3′-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994.